Medigene AG
0.0M
$38.17M
-1.90
$-1.32
No price alerts set. Add an alert to get notified!
-1.90
1.46
$-1.32
-76.79%
-268.10%
-267.63%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
CAIHF
Chia Tai Enterprises International Limited
|
$0.28 | 0.00 | 7.34 | $217.44M | 0.17 |
|
EMBT
Ember Therapeutics, Inc.
|
$0.00 | 0.00% | -0.02 | $398 | -0.84 |
|
ENZC
Enzolytics Inc.
|
$0.00 | 50.00% | -2.56 | $1.18M | -0.01 |
|
GRTX
Galera Therapeutics, Inc.
|
$0.05 | -2.49% | -0.52 | $3.55M | 0.00 |
|
MJARF
MJardin Group, Inc.
|
$0.00 | 0.00 | 0.00 | $90,140 | -1.92 |
|
MODVQ
ModivCare Inc.
|
$0.02 | 0.00 | 0.00 | $215,307 | -3.26 |
|
NBCO
Neon Bloom, Inc.
|
$0.01 | 0.00 | -0.96 | $1.40M | -0.10 |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | 0.00% | 0.69 | $1.64M | 0.00 |
|
SZLSF
StageZero Life Sciences Ltd.
|
$0.00 | 0.00 | 0.00 | $61,766 | -0.24 |
|
VCNX
Vaccinex, Inc.
|
$1.09 | 9.22% | -0.25 | $2.92M | -0.01 |
* Peer stocks are selected based on market capitalization and sector
$2.59
$0.10
$0.00
0.00%
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
